Cat­a­lyst Phar­ma­ceu­ti­cals to ac­quire com­mer­cial rights to an Ei­sai seizure med­ica­tion for $160M

Cat­a­lyst Phar­ma­ceu­ti­cals is adding an­oth­er drug to its ar­se­nal by pick­ing up a drug from Ei­sai.

The Flori­da-based rare dis­ease biotech an­nounced on Mon­day that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER